Confidently prescribe NUPLAZID, a single once-daily capsule, for appropriate patients with hallucinations and delusions associated with PD psychosis.1,2

NUPLAZID Dosing

ONE FDA-approved treatment1,2

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

FDA–approved icon shows NUPLAZID® as an approved medication to treat hallucinations & delusions associated with PD psychosis

ONE small* capsule

  • 34 mg in one single capsule
*Actual size is 14.4 mm x 5.3 mm.
Angle view image of pimavanserin (NUPLAZID®) 34 mg capsule (does not reflect actual size)

ONCE daily, taken whole or sprinkled

  • Taken orally with or without food, without titration

  • The capsule can be opened and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. The food/drug mixture should be consumed immediately without chewing; do not store for future use

  • No dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID

  • No dosage adjustment in elderly patients, patients with mild to severe renal impairment or end-stage renal disease (ESRD), or in patients with hepatic impairment

Increased exposure (Cmax and AUC) to NUPLAZID occurred in patients with severe renal impairment (CrCl <30 mL/min, Cockcroft-Gault) in a renal impairment study. NUPLAZID should be used with caution in patients with severe renal impairment and ESRD.1

Illustration of 1x to represent once daily dose of NUPLAZID®

Dosing considerations

  • For patients taking strong CYP3A4 inhibitors, the recommended dose of NUPLAZID is one 10 mg tablet daily

  • Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID

  • Avoid the use of NUPLAZID in combination with other drugs known to prolong the QT interval

Drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. In the 6-week, placebo-controlled studies, mean increases of QTc interval of ~5.8 msec were observed in NUPLAZID-treated patients.1

The steady-state plasma concentration of NUPLAZID was reached in ~12 days with continuous treatment, without titration3

Simulation of a typical plasma concentration (Cp) profile of NUPLAZID3

Graph shows steady–state plasma concentration of NUPLAZID®
Graph shows steady–state plasma concentration of NUPLAZID®
Half-life (t1/2) is 57 hours.¹

Download a helpful dosing guide for NUPLAZID.

Acadia Connect makes it easy to get patients started on their PD psychosis treatment.

IMPORTANT SAFETY INFORMATION and INDICATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation

    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.

    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

  • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

  • Drug Interactions:

    • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.

    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

References:
  1. Acadia Pharmaceuticals Inc. NUPLAZID® [package insert]. San Diego, CA; 2020.
  2. US Food and Drug Administration. FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm498442.htm. Updated March 1, 2019. Accessed August 13, 2019.
  3. Acadia Pharmaceuticals Inc. NUPLAZID Advisory Committee Briefing Document. San Diego, CA: Sponsor Background Information for a Meeting of the Psychopharmacologic Drugs Advisory Committee; March 29, 2016. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM492453.pdf. Accessed June 17, 2020.